|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Cephalon |
|---|---|
| Information provided by: | Cephalon |
| ClinicalTrials.gov Identifier: | NCT00080288 |
Purpose
The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with chronic shift work sleep disorder (SWSD) by measuring mean sleep latency from the Multiple Sleep Latency Test (MSLT) (20 minutes) (average of 4 naps at 0200, 0400, 0600, and 0800) and by Clinical Global Impression of Change (CGI-C) ratings.
| Condition | Intervention | Phase |
|---|---|---|
|
Excessive Sleepiness Shift Work Sleep Disorder |
Drug: Armodafinil 150 mg/day Drug: Placebo |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder |
| Enrollment: | 254 |
| Study Start Date: | March 2004 |
| Estimated Study Completion Date: | December 2004 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Armodafinil 150 mg/day
|
Drug: Armodafinil 150 mg/day
Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
|
|
Placebo Comparator: 2
Placebo
|
Drug: Placebo
Matching placebo tablets once daily
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients are included in the study if all of the following criteria are met:
Exclusion Criteria:
Patients are excluded from participating in this study if 1 or more of the following criteria are met:
Contacts and Locations
More Information
| ClinicalTrials.gov Identifier: | NCT00080288 History of Changes |
| Other Study ID Numbers: | C10953/3022/CM/MN |
| Study First Received: | March 25, 2004 |
| Results First Received: | June 1, 2009 |
| Last Updated: | May 14, 2010 |
| Health Authority: | United States: Food and Drug Administration |
|
Excessive Sleepiness Chronic Shift Work Sleep Disorder Chronic SWSD Circadian Rhythm Disorder |
Shift Worker Cephalon Cephalon, Inc Nuvigil |
|
Sleep Disorders Parasomnias Sleep Disorders, Circadian Rhythm Disorders of Excessive Somnolence Nervous System Diseases Neurologic Manifestations Signs and Symptoms Mental Disorders Chronobiology Disorders Dyssomnias |
Occupational Diseases Sleep Disorders, Intrinsic Modafinil Central Nervous System Stimulants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Neuroprotective Agents Protective Agents |